Gut microbial metabolite 4-hydroxybenzeneacetic acid drives colorectal cancer progression via accumulation of immunosuppressive PMN-MDSCs

Qing Liao, Xin‐Hui Zhou, Ling Wu, Yuyi Yang, Xiaohui Zhu, Hangyu Liao, Yujie Zhang, Weidong Lian, Feifei Zhang, Hui Wang, Yanqing Ding, Liang ZhaoJournal of Clinical Investigation 2025 · DOI

TL;DR

This study reveals how a specific gut microbial metabolite, 4-hydroxybenzeneacetic acid (4-HPA), drives colorectal cancer (CRC) progression by promoting an immunosuppressive tumor microenvironment. 4-HPA activates a key signaling pathway (JAK2/STAT3) in cancer cells, leading to the production of CXCL3, which recruits immunosuppressive myeloid-derived suppressor cells (MDSCs). This mechanism hinders anti-tumor immune responses and reduces the effectiveness of immunotherapy, offering potential new therapeutic targets.

What Problem Does This Paper Address?

Colorectal cancer (CRC) is a major global health challenge, often characterized by an immune-suppressive tumor microenvironment that limits the effectiveness of treatments, particularly immunotherapy. While the gut microbiome is known to influence cancer development and treatment response, the specific roles of individual microbial metabolites in shaping this microenvironment remain largely unknown. This paper aims to unravel how specific gut bacteria and their metabolites contribute to CRC progression by creating an immunosuppressive milieu, thereby identifying potential targets for improving cancer therapy.

Methods

The researchers employed a multi-pronged approach:

  • Metagenomic Sequencing: To identify differences in gut microbial composition between CRC patients and healthy controls.
  • Cytokine Antibody Array & qPCR/ELISA: To screen and quantify cytokine and chemokine secretion from CRC cells stimulated by specific bacteria.
  • Animal Models:
    • Apcmin/+ tumorigenesis model: To study the impact of gut microbiota imbalance on spontaneous tumor development.
  • Orthotopic implanted CRC mouse model: To investigate the role of specific bacteria and metabolites in established tumors.
  • Subcutaneous tumor models: To evaluate the effects of gene knockdown and therapeutic interventions.
  • Flow Cytometry: To analyze the infiltration and function of various immune cells (PMN-MDSCs, M-MDSCs, CD8+ T cells, Tregs) within tumors.
  • Immunofluorescence (IF) & Immunohistochemistry (IHC): To visualize the expression and localization of key proteins (e.g., CXCR2, Gr-1, STAT3, p-STAT3) in tumor tissues.
  • Western Blot (WB): To assess the activation of signaling pathways (JAK2/STAT3) and protein expression.
  • ChIP Assays & Dual-Luciferase Reporter Assays: To confirm the binding of transcription factors to the CXCL3 promoter.
  • Nontargeted Metabolomics (GC-MS/MS): To identify differential metabolites produced by imbalanced gut microbiota.
  • Transwell Assays: To evaluate the chemotactic effects of CXCL3 on MDSCs.
  • In vivo PD-1 Immunotherapy Studies: To assess the impact of 4-HPA and CXCL3 knockdown on the efficacy of anti-PD-1 therapy.
  • Clinical Sample Analysis: HRGC-MS to measure 4-HPA levels in human CRC tissues and IF to correlate CXCL3 expression with immune cell infiltration.

Datasets

  • Human CRC Tissues: Used for HRGC-MS analysis of 4-HPA levels and for multiplex IF to assess the correlation between CXCL3 expression and immune cell infiltration.
  • Fecal Samples: From 20 CRC patients and 20 healthy controls, used for metagenomic sequencing.
  • CRC Cell Lines: SW480, HCT116, RKO, and CT26 (mouse colon carcinoma cell line) were used for in vitro experiments.

Key Insights and Ideas

  • Gut Microbiota as a "Messenger": The study highlights how gut microbial metabolites can act as messengers, translating microbial signals into host immune responses that influence cancer progression. 4-HPA is presented as a prime example of such a messenger.
  • CXCL3 as a Central Player: CXCL3 emerges as a critical chemokine that bridges the gap between microbial metabolites and immune suppression, specifically by recruiting PMN-MDSCs. Its role in inhibiting CD8+ T cell function is a key finding.
  • JAK2/STAT3 Pathway as the Molecular Switch: The identification of the JAK2/STAT3 pathway as the mechanism by which 4-HPA upregulates CXCL3 provides a concrete molecular link. This pathway is a well-established player in cancer, and its activation by a microbial metabolite is a significant discovery.
  • Reversing Immunosuppression: The study demonstrates that targeting 4-HPA production (e.g., with chlorogenic acid) or its downstream effects (e.g., CXCL3 knockdown) can reverse the immunosuppressive microenvironment and enhance anti-tumor immunity, even improving the efficacy of immunotherapy.
  • Clinical Relevance of 4-HPA: The finding that 4-HPA levels are elevated in advanced CRC patients underscores its potential as a biomarker and therapeutic target in human disease.

Key Results

  • Microbial Dysbiosis in CRC: Patients with CRC showed reduced gut microbial diversity and altered community structure compared to healthy controls, with Fusobacterium nucleatum and E. coli being enriched.
  • Bacterial Stimulation of Chemokines: F. nucleatum and E. coli significantly stimulated CRC cells to secrete chemokines like CCL20 and CXCL3.
  • CXCL3 Drives Immunosuppression: Knockdown of CXCL3 in mouse models significantly reduced tumor growth, decreased PMN-MDSC infiltration, and increased CD8+ T cell activity, thereby enhancing anti-tumor immunity.
  • 4-HPA as the Metabolite Driver: Nontargeted metabolomics identified 4-HPA as a key metabolite produced by imbalanced gut microbiota that strongly induces CXCL3 secretion in CRC cells.
  • 4-HPA Activates JAK2/STAT3: 4-HPA activates the JAK2/STAT3 pathway, leading to increased CXCL3 transcription.
  • 4-HPA Promotes MDSC Recruitment: In vivo, 4-HPA administration led to increased PMN-MDSC accumulation and decreased CD8+ T cell function in tumors.
  • Chlorogenic Acid Reverses Effects: Chlorogenic acid (CGA), which reduces 4-HPA production, reversed the immunosuppressive effects of F. nucleatum and E. coli, reducing tumor burden and restoring CD8+ T cell function.
  • 4-HPA Impairs Immunotherapy: 4-HPA blocked the efficacy of anti-PD-1 immunotherapy in mouse models.
  • Clinical Correlation: 4-HPA levels were higher in advanced CRC patients, and CXCL3 expression in human tumors negatively correlated with CD8+ T cell infiltration and positively correlated with MDSC infiltration.

Limitations and Future Work

  • Specificity of Bacteria: While F. nucleatum and E. coli were identified, the study acknowledges that other bacteria and their metabolites could also contribute to the CRC microenvironment.
  • Complexity of the Microbiome: The study focuses on specific bacteria and metabolites, but the gut microbiome is a complex ecosystem, and interactions between multiple species and metabolites are likely to be important.
  • Translational Potential: While promising, further research is needed to translate these findings into clinical interventions, such as developing targeted therapies or dietary interventions to modulate 4-HPA levels.
  • Mechanisms of 4-HPA Action: While the JAK2/STAT3 pathway is identified, the precise upstream mechanisms by which 4-HPA activates this pathway warrant further investigation.
  • Role of M-MDSCs: The study found no significant difference in M-MDSC infiltration, but their role in the context of 4-HPA and CXCL3 signaling might require further exploration.

The authors suggest that their findings provide a scientific basis for developing clinical strategies to reverse the tumor immune microenvironment and improve immunotherapy efficacy by modulating the interactions between the gut microbiota, tumor cells, and tumor immune cells.

Summary updated

Abstract

Colorectal cancer (CRC) is characterized by an immune-suppressive microenvironment that contributes to tumor progression and immunotherapy resistance. The gut microbiome produces diverse metabolites that feature unique mechanisms of interaction with host targets, yet the role of many metabolites in CRC remains poorly understood. In this study, the microbial metabolite 4-hydroxybenzeneacetic acid (4-HPA) promoted the infiltration of PMN myeloid-derived suppressor cells (PMN-MDSCs) in the tumor microenvironment, consequently inhibiting the antitumor response of CD8+ T cells and promoting CRC progression in vivo. Mechanistically, 4-HPA activates the JAK2/STAT3 pathway, which upregulates CXCL3 transcription, thereby recruiting PMN-MDSCs to the CRC microenvironment. Selective knockdown of CXCL3 resensitized tumors to anti-PD-1 immunotherapy in vivo. Chlorogenic acid reduces the production of 4-HPA by microbiota, likewise abolishing 4-HPA-mediated immunosuppression. The 4-HPA content in CRC tissues was notably increased in patients with advanced CRC. Overall, the gut microbiome uses 4-HPA as a messenger to control chemokine-dependent accumulation of PMN-MDSC cells and regulate antitumor immunity in CRC. Our findings provide a scientific basis for establishing clinical intervention strategies to reverse the tumor immune microenvironment and improve the efficacy of immunotherapy by reducing the interaction among intestinal microbiota, tumor cells, and tumor immune cells.
BibTeX
@article{liao2025gut,
  author = {Qing Liao and Xin‐Hui Zhou and Ling Wu and Yuyi Yang and Xiaohui Zhu and Hangyu Liao and Yujie Zhang and Weidong Lian and Feifei Zhang and Hui Wang and Yanqing Ding and Liang Zhao},
  title = {{Gut microbial metabolite 4-hydroxybenzeneacetic acid drives colorectal cancer progression via accumulation of immunosuppressive PMN-MDSCs}},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci181243},
}
Figure